Plasma cell myeloma and related neoplasms

American Journal of Clinical Pathology

Volumn 136, Issue 2, 2011, Pages 168-182

  Lorsbach, Robert B ^a   Hsi, Eric D ^b   Dogan, Ahmet ^c   Fend, Falko ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Lymphoid malignancies; Neoplasms; Nonsecretory plasmacytoma; Plasma cell myeloma; Plasmablastic transformation; t(11; 14): Plasma cell leukemia

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD79 ANTIGEN; CYCLIN D1; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; STEM CELL FACTOR RECEPTOR; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5;

B LYMPHOCYTE; CHROMOSOME 11; CLINICAL FEATURE; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOPHENOTYPING; LYMPHOCYTE; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; PARAPROTEINEMIA; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PRIORITY JOURNAL;

HUMANS; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL;

EID: 79961010384     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPENJ68FFBRIYB     Document Type: Conference Paper

References (71)

1. Chng WJ, Glebov O, Bergsagel PL, et al. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007;20:571-596. (Pubitemid 350215376)
2. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333-6338. (Pubitemid 46218843)
3. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood. 2001;98:3082-3086.
4. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A. 2000;97:228-233. (Pubitemid 30055813)
5. Liang W, Hopper JE, Rowley JD. Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders. Cancer. 1979;44:630-644. (Pubitemid 10220148)
6. Chesi M, Bergsagel PL, Brents LA, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674-681. (Pubitemid 26240399)
7. Hoyer JD, Hanson CA, Fonseca R, et al. The (11;14) (q13;q32) translocation in multiple myeloma: a morphologic and immunohistochemical study. Am J Clin Pathol. 2000;113:831-837. (Pubitemid 33051519)
8. Cook JR, Hsi ED, Worley S, et al. Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival. Am J Clin Pathol. 2006;125:615-624.
9. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33. (Pubitemid 36033957)
10. Slotta-Huspenina J, Koch I, Richter M, et al. Cyclin D1 positive multiple myeloma: predominance of the short, 3′UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions. Leuk Res. 2008;32:79-88. (Pubitemid 350100855)
11. Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102:1070-1071. (Pubitemid 36917806)
12. Lin P, Hao S, Handy BC, et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005;123:200-205. (Pubitemid 40194080)
13. Feyler S, O'Connor SJ, Rawstron AC, et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117-immunophenotype and the t(11;14). Br J Haematol. 2008;140:547-551. (Pubitemid 351230082)
14. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
15. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97:2900-2902.
16. Dul JL, Argon Y. A single amino acid substitution in the variable region of the light chain specifically blocks immunoglobulin secretion. Proc Natl Acad Sci U S A. 1990;87:8135-8139.
17. Coriu D, Weaver K, Schell M, et al. A molecular basis for nonsecretory myeloma. Blood. 2004;104:829-831. (Pubitemid 38970581)
18. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood. 2001;97:822-825. (Pubitemid 32113422)
19. Avet-Loiseau H, Garand R, Lode L, et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570-1571. (Pubitemid 36182536)
20. Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044-1052. (Pubitemid 351689887)
21. Jones D, Bhatia VK, Krausz T, et al. Crystal-storing histiocytosis: a disorder occurring in plasmacytic tumors expressing immunoglobulin kappa light chain. Hum Pathol. 1999;30:1441-1448. (Pubitemid 30032920)
22. Lebeau A, Zeindl-Eberhart E, Muller EC, et al. Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature. Blood. 2002;100:1817-1827. (Pubitemid 34925162)
23. Seegmiller AC, Xu Y, McKenna RW, et al. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol. 2007;127:176-181. (Pubitemid 46797173)
24. Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Mod Pathol. 2009;22:807-816.
25. Brouet JC, Fermand JP, Laurent G, et al. The association of chronic lymphocytic leukaemia and multiple myeloma: a study of eleven patients. Br J Haematol. 1985;59:55-66. (Pubitemid 15188819)
26. Fermand JP, James JM, Herait P, et al. Associated chronic lymphocytic leukemia and multiple myeloma: origin from a single clone. Blood. 1985;66:291-293. (Pubitemid 15007014)
27. Kaufmann H, Ackermann J, Nosslinger T, et al. Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma: a report on two cases. Ann Hematol. 2001;80:474-478. (Pubitemid 32771611)
28. Chang H, Wechalekar A, Li L, et al. Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. Cancer Genet Cytogenet. 2004;148:44-48. (Pubitemid 38018879)
29. Pantic M, Schroettner P, Pfeifer D, et al. Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma. Leukemia. 2010;24:885-890.
30. Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia: report on 17 cases. Arch Intern Med. 1974;133:813-818.
31. Dimopoulos MA, Palumbo A, Delasalle KB, et al. Primary plasma cell leukaemia. Br J Haematol. 1994;88:754-759. (Pubitemid 24375790)
32. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037. (Pubitemid 29067869)
33. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78:288-294. (Pubitemid 40471121)
34. Tanioka F, Tamashima S, Shimizu S, et al. A case of primary plasma cell leukemia with hairy-cell morphology and lambda-type Bence-Jones protein: immunohistochemical and molecular analysis. Jpn J Clin Oncol. 2003;33:232-237. (Pubitemid 43115264)
35. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977-1982. (Pubitemid 28554471)
36. Gutierrez NC, Hernandez JM, Garcia JL, et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia. 2001;15:840-845. (Pubitemid 32492709)
37. Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48:624-636.
38. Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717-726. (Pubitemid 38365776)
39. Dores GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol. 2009;144:86-94.
40. Knobel D, Zouhair A, Tsang RW, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118. doi:10.1186/1471-2407-6-118.
41. Ramsingh G, Mehan P, Morgensztern D, et al. Prognostic factors influencing survival in solitary plasmacytoma. Br J Haematol. 2009;145:540-542.
42. Kremer M, Ott G, Nathrath M, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol. 2005;205:92-101. (Pubitemid 40029097)
43. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93:623-626. (Pubitemid 351536395)
44. Bartl R, Frisch B, Burkhardt R, et al. Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51:361-375. (Pubitemid 12045309)
45. Bartl R, Frisch B, Fateh-Moghadam A, et al. Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol. 1987;87:342-355. (Pubitemid 17046985)
46. Greipp PR, Raymond NM, Kyle RA, et al. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305-310. (Pubitemid 15163565)
47. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501-2507. (Pubitemid 28155526)
48. Rajkumar SV, Fonseca R, Lacy MQ, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999;17:1551-1557. (Pubitemid 29220864)
49. Weh HJ, Bartl R, Seeger D, et al. Correlations between karyotype and cytologic findings in multiple myeloma. Leukemia. 1995;9:2119-2122. (Pubitemid 26023799)
50. Kapoor P, Kumar S, Fonseca R, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009;114:518-521.
51. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522-525.
52. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117:103-108. (Pubitemid 34304427)
53. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21. (Pubitemid 28018724)
54. Neri A, Murphy JP, Cro L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med. 1989;170:1715-1725. (Pubitemid 19284568)
55. Portier M, Moles JP, Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539-2543.
56. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood. 1996;88:2699-2706. (Pubitemid 26327523)
57. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-809. (Pubitemid 28355463)
58. Avet-Loiseau H, Li JY, Godon C, et al. p53 deletion is not a frequent event in multiple myeloma. Br J Haematol. 1999;106:717-719. (Pubitemid 29434212)
59. Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 2001;18:212-224. (Pubitemid 32807900)
60. Chang H, Qi C, Yi QL, et al. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005;105:358-360. (Pubitemid 40053104)
61. Chiecchio L, Dagrada GP, Protheroe RK, et al. Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica. 2009;94:1024-1028.
62. Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group Molecular Classification of Multiple Myeloma: spotlight review. Leukemia. 2009;23:2210-2221.
63. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611-5622.
64. Chesi M, Kuehl WM, Bergsagel PL. Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma. Ann Oncol. 2000;11(suppl 1):131-135.
65. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413-1420. (Pubitemid 27080006)
66. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736-747. (Pubitemid 38685887)
67. Aguilera NS, Kapadia SB, Nalesnik MA, et al. Extramedullary plasmacytoma of the head and neck: use of paraffin sections to assess clonality with in situ hybridization, growth fraction, and the presence of Epstein-Barr virus. Mod Pathol. 1995;8:503-508.
68. Chang ST, Liao YL, Lu CL, et al. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol. 2007;128:339-344.
69. Bogusz AM, Seegmiller AC, Garcia R, et al. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132:597-605.
70. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features [published online ahead of print March 26, 2010]. Mod Pathol. 2010;23:991-9999. doi:10.1038/modpathol.2010.72.
71. Dong HY, Scadden DT, de Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29:1633-1641.